PRTN3 and rheumatoid arthritis: A meta-analysis of four randomized placebo-controlled trials from the rituximab clinical programme confirmed the additional treatment benefit in autoantibody-positive RA, particularly in patients for whom at least one TNF inhibitor had failed, and without significant differences between RF and ACPA (100).